CD19/22 CAR-T for certain B-cell blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a lab-made immune treatment (CAR-T cells) designed to attack cancer cells that carry CD19 or CD22. It may help people whose B-cell cancers have those markers, provided they meet safety and health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be older than 6 months
- Have a B-cell blood cancer with CD19 or CD22 on the cancer cells
- Be well enough for treatment (KPS over 80) and have more than 1 month expected survival
- Have hemoglobin above 80 g/L (enough blood count to safely proceed)
- Be able to have blood or stem cell collection for the treatment
- Not have uncontrolled infection or other serious conditions that could block measuring your response
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This early-phase trial tests a customized immune cell therapy (CAR-T) that targets cancer cells with CD19 or CD70 markers on their surface. It may help your body fight the cancer by directing new immune cells to recognize and attack those cells.
This trial tests a new treatment using your own immune cells (T-cells) that are modified to find and attack cancer cells with a marker called CD22. It is for people with B-cell blood cancers that have come back or not responded to at least two prior treatments, including a type of immunotherapy called CAR T-cell therapy.
This trial tests a lab-made immune therapy called CAR-T that targets specific markers on B-cell leukemia/lymphoma cells. It may help people whose cancer has returned or did not respond after earlier CD19 CAR-T, by attacking the cancer cells using added targeting.
This trial tests a new type of CAR-T cell therapy that targets multiple markers on B-cell lymphoma cells. It is for patients whose lymphoma has certain surface markers and who are in reasonably good health.
This trial studies a type of immune treatment (CAR-T cells) designed to calm overactive immune disease. It may help by aiming the therapy at immune cells involved in B-cell activity, but it has strict health and safety requirements.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.